-
Ucello Biotech’s UC101 Receives FDA IND Clearance for Anti-CD19 Therapy
•
China-based Chengdu Ucello Biotechnology Co., Ltd., a developer of allogeneic universal chimeric antigen receptor (CAR)-T cell therapies, has announced receiving Investigational New Drug (IND) clearance from the US FDA for its anti-CD19 allogeneic universal T-cell therapy UC101. This clearance is a significant milestone in the development of UC101, paving the…
-
Ucello Therapeutics Secures RMB 150 Million in Series A+ Financing for CAR-T Cell Therapy
•
Ucello Therapeutics, a developer of allogeneic universal chimeric antigen receptor (CAR)-T cell therapies based in Chengdu, has reportedly raised RMB 150 million (USD 21.2 million) in a Series A+ financing round. The funding was led by Juke Investment, with contributions from Guozhong Capital and Penglai Capital, as well as existing…
